« Previous article
US Defense Contracte...

8th October 2021  Product update: ANP Technologies

Commerical Rapid Neutralizing Antibody Test Shows Waning Levels Post COVID-19 Vaccination


A commercially available rapid neutralizing antibody (NAb) test has recorded significant decreases in SARS-CoV-2 NAb levels in individuals 2-6 months after receiving 2nd Pfizer, and Moderna vaccinations claim a study published on pre-print server medRxiv. 

The study lasting 7-weeks, from 29 June - 17 August, and involving 164 fully vaccinated individuals, was conducted to investigate the need to screen fully vaccinated individuals who might be vulnerable to breakthrough infection (infection despite being vaccinated).

The paper: COVID-19 Neutralizing Antibody Surveillance Testing for Fully Vaccinated Individuals During Delta Variant Spread has been published on medRxiv, the pre-print server, and was carried out by ANP Technologies; manufacturers of the NIDS® COVID-19 Neutralizing Antibody (NAb) Test used. 

The NAb test is a rapid, competitive lateral-flow Immunoassay for the qualitative or semi-quantitative detection of total antibodies that block the interactions between SARS-CoV-2 S/RBD protein and ACE2 receptor binding.

The test has a limit of detection (LoD) of 0.5µg/ml, but as some participants with these levels of NAb had contracted the Delta and Mu strains, it was decided to increase the cut-off point to 1 µg/m, and anything less classified as non-responsive/showing no protection. 

The study highlighted how NAb levels post-vaccination varied and depended on several factors; health condition, age, etc. The results demonstrate the usefulness of rapid neutralizing antibody tests in broader society as people return to everyday life, while the debate on booster shots for the general population continues.

To learn more about the NIDS test, visit ANP's website or send a request for more info using the button below. 


    

Tags:

Date Published: 8th October 2021

Source article link: View

Note: This content has been edited by a rapidvirology.com staff writer for style and content.


View full company details


Related news